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ABSTRACT
Myeloablative conditioning followed by T-cell depletion of grafts and reduced intensity conditioning (RIC) has
both been shown to decrease treatment relatedmortality (TRM). However in RIC the incidence of graft vs. host
disease (GvHD) is high and patients with aggressive diseases tend to relapse. Followingmyeloablative condition-
ing, patients with chemotherapy-responsive heamatological malignancies underwent transplantation fromHLA
identical siblings. GvHD prophylaxis was by ex viva T-cell depletion with alemtuzumab. The outcome of these
patients was analysed. At transplantation, the median age of 81 consecutive individuals was 45 years (range
15-60). GvHD was seen in 10% and was commonly associated with infections resulting in one and 3 year
TRM of 15 and 20.5%. Fifteen patients relapsed, 10 who had myeloproliferative syndromes or lymphoma and
two with myeloma responded to DLI. For the whole group, median follow up is 777 (range 7-2702) days and
73% remain disease free. Cox regression analysis for survival showed that only occurrence of GvHDwas a signif-
icant adverse factor. Age order than median was not associated with worse outcome. By reducing the incidence
and severity of GvHD, T-cell depletion of grafts leads to greater tolerance to myeloablative chemotherapy,
resulting in acceptable TRM. This strategy should be compared with the RIC approaches.
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Allogeneic stem cell transplantation still remains
the only curative therapy for a number of hematological
disorders [1-9].However, thismodality has been associ-
ated with substantial side effects from the conditioning,
the post transplant immunosuppression, and from the
morbidity and mortality of graft-versus-host disease
(GVHD) [4-6]. The observation that potent immuno-
depletion, but not necessarily fullmyeloablation, is nec-
essary for engraftment has led to a number of studies
with thismethodology, aimingatminimizingdisease re-
lapse, graft rejection, and GVHD [7-10]. In contrast to
conventional strategies, reduced-intensity conditioning
(RIC) regimens are profoundly immunosuppressive,
but have lower acute toxicity, leading to 1-yr treat-
ment-related mortality (TRM) in the range of 10% to
15%. Thus, RIC has extended the benefit of the graft-versus-tumor effect to patients who are not candidates
for fully ablative conditioning by virtue of their age or
existing co-morbidities [8,9]. However, as ablative con-
ditioning schedules, RIC strategies are fraught with
other similar difficulties including GVHD, infectious
complications, and a somewhat increased rate of graft
rejection as well as disease relapse [9,10]. The anti-tu-
mor effect of this approach is less well established, as
long-term disease specific outcome data is still limited.
As an alternative and to reduce conditioning toxic-
ity, immune modulation with antibodies has been used
extensively for the dual purpose of host immunosup-
pression and for in vivo or ex-vivo T cell depletion
[11,12]. The efficacy of antithymocyte globulin
(ATG) in preventing graft rejection is well established,
and it is considered a crucial component in most
mismatched transplantation regimens. Its role in the
prevention of GVHD is more controversial [12].709
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effective strategy in the prevention of GVHD, even
when a larger load of T cells are present, as occurs in
a peripheral blood progenitor cell graft (PBPC)
[11,14,15]. Experience has shown that with some of
these strategies, lower incidence and severity of GVHD
have been associated with improvement in the early
outcome after transplantation and may also have a fa-
vorable impact on overall survival (OS). For this rea-
son, we have prospectively studied and are now
reporting on the outcome of individuals with hema-
tological malignancies who received uniform ex vivo
T cell depletion of the stem cell grafts with alemtu-
zumab. We show that in the absence of clinical fea-
tures of GVHD, patients can successfully undergo
myeloablative conditioning with acceptable TRM
and good long-term control of the malignancy.
PATIENTS AND METHODS
The main focus of this study was to determine the
overall rate of OS for a protocol of GVHD prophylaxis
by ex vivo lymphocyte depletion with alemtuzumab
(CAMPATH-1H; antiCD52) in patientswith hemato-
logical malignancies. The secondary end points in-
cluded determination of rate of TRM, GVHD, and
malignant disease recurrence. In this prospective study,
we included all consecutive individuals up to the age of
60 yrs referred between July 2000 and January 2006 for
allogeneic transplantation from their HLA identical
siblings. Entry criteria required adequate performance
status (0, 1 or 2), non-reactivity on testing for the hu-
man immunodeficiency virus (HIV), and chemother-
apy responsive malignancy.
Patients with acute myelogenous leukemia (AML)
were stratified according to cytogenetic risk [16].
Those with high and intermediate risk were offered
transplantation in complete remission (CR)1. Individ-
uals with low karyotype risk were also referred to SCT
if they had other unfavorable risk factors such as hyper-
leucocytosis (n5 5) [17] or extramedullary masses
(n51) [18] that led to the indication for the procedure.
Individuals with lymphoid leukemia were offered
transplantation in CR 1 if they had, on presentation,
poor prognostic factors (unfavorable cytogenetics,
leukokyte count. 35  109/L, meningeal leukemia).
Subjects with follicular (responsive to salvage therapy,
first clinical response shorter than 1 year, or trans-
formed malignancy), mantle, or peripheral T cell lym-
phoma in second or further chemo-sensitive response
were also offered this procedure. In addition, patients
with lymphoma who failed to mobilize sufficient stem
cells for autologous transplantation and had a compat-
ible sibling were also offered transplantation. Before
the availability of imatinib mesylate, individuals with
chronic phase chronic myelogenous leukemia (CML)
were also offered this strategy. Patients with multiplemyeloma were initially treated with dexamethazone
based programs (C-VAD [cyclophosphamide-vincris-
tine, adriamycin, dexamethazone], dexamethazone
and thalidomide). Three patients had also received
PBPC autologous stem cell graft following melphalan
200 mg/m2 conditioning. All patients with myeloma
had achieved CR or partial remission (PR) [13]. The
details of our therapies have been published elsewhere
[15,18,9].
Myeloablative conditioning
Two myeloablative conditioning protocols were
used during the trial. One was radiotherapy based;
while the other included cytotoxic agents only. The
allocation of the type of conditioning was derived
from the availability of radiotherapy space in a busy
tertiary hospital oncology program. The radiation-
based conditioning regimen was with fractionated
total body irradiation (TBI) delivered in 6, twice daily
fractions of 2 Gy (total 1200cGy), 4 fractions of total
lymphoid irradiation of 1.5 Gy followed by cyclophos-
phamide 60 mg/kg (with mesna cover) on days -2 and
1 [19]. Patients with multiple myeloma were also con-
ditioned with radiotherapy, but melphalan at 100
mg/m2, replaced cyclophosphamide. When radiother-
apy was not available, individuals received conditioning
with oral busulfan 1mg/ kg 12, melphalan 70 mg/m2
on 2 consecutive days (total dose 140mg/m2), followed
by cyclophosphamide 60 mg/kg on each of two con-
secutive days. Post transplantation patients received
valacyclovir 1 g 8 hourly, and after engraftment, co-
trimoxazole 80 mg for 3 mos. Following leukocyte re-
covery, cytomegalovirus (CMV) reactivation was
monitored by weekly pp65 determination. Reactiva-
tion of CMV was treated with gancyclovir 5mg/kg,
twice daily for 14 days followed by gancyclovir 3mg/
kg daily or oral valgancyclovir for 3 mos.
Collection of stem cells for transplantation
For the mobilization of marrow progenitors, HLA
identical sibling donors were treated with granulocyte–
colony-stimulating factor (G-CSF) 5-10 mg/kg/day
injected subcutaneously on 5 consecutive days. Large
volume apheresis was started approximately 4 hrs
after the last dose of G-CSF. The number of CD341
cells was determined according to the guidelines of
the International Society for Hematotherapy andGraft
Engineering [20]. Based on the patient’s ideal body
weight, the target cell dose was 2  106 CD341 cells/
kg. In the event that the target cell dose was not
achieved, apheresis was repeated the following day.
Only 7 donors were subjected to more than 2 collec-
tions. To confirm engraftment, we determined origin
of hematopoiesis by standard cytogenetic analysis at
3 mos post transplantation, based on sex chromo-
some differences between donor and recipient.
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Stem cell rich products were then treated with
alemtuzumab [15, 18] and 1-2 mg /1010 MNC cells
was added ‘‘into the bag,’’ allowed to react at 20C
for 30 min. Without further manipulation, the cell
suspension containing the antibody was then infused
intravenously over 30 to 60min using intravenous lines
devoid of any filters. Initially, the dose of alemtuzumab
was of 2 mg /1010 mononuclear cells (MNC), but after
an interim analysis suggested better outcome with
lower dose of the antibody [15], to reduce immunosup-
pression, in 2002, the dose was halved. Intravenous cy-
closporinwas commenced on day –1 at a dose of 3mg/kg
in 2 divided doses, maintaining always a therapeutic
serum level. Upon recovery of the gastrointestinal
tract from the effects of the conditioning, cyclosporin
was continued as an oral formulation until day 90.
Graft-versus-Host Disease
GVHD was defined according to the Seattle crite-
ria [21]. Acute GVHD (aGVHD; grades II-IV), was
treated with systemic prednisone (2-10 mg/kg/day)
with or without cyclosporin (with close monitoring
of blood levels). Once this phenomenon was con-
trolled, immunosuppression was tapered off according
to clinical response.
Donor lymphocyte harvests and infusions [22]
When patients relapsed, the donor underwent
apheresis and the harvested blood MNC population
was defined by flowcytometry using a 2-color protocol.
Aliquots containing CD31 cells were prepared start-
ing at 5-10  106/kg, at 1⁄2 log increments, to a total
cell number of 100 to 500  106/kg recipients’ weight.
Aliquots were cryopreserved with controlled rate
freezer at 1C/min to -80C, and stored in liquid nitro-
gen tanks (Linde, Norway). At the assigned periods, al-
iquots with the lowest CD31 cell fraction were thawed
and infused intravenously without pre-medication. Pa-
tients were observed for clinical evidence of GVHD
and 4-6 wks later marrow samples were obtained for
the required morphological, cytogenetic and/or mo-
lecular studies (paraprotein level in myeloma) to deter-
mine response. If the disease status remained constant,
the next CD31 cell increment was infused. When
GVHD was suspected/confirmed and, if a reduction
in blood counts or Ph1 cells (or paraprotein level)
was noted, the next infusion was withheld. Thereafter,
another bone marrow / blood sample was re-tested 2-4
wks later. For patients with myeloma, at disease recur-
rence, a similar schedule was prepared except that the
starting infusion dose was 1  107/kg CD3 cells.
Statistical Analysis
The chi-square statistic or Fisher’s exact tests were
used to establish differences in the distribution of dis-continuous variables and Student’s t-test to compare
continuous variables. All reported P values are 2-sided.
Characteristics of treatment groups and outcomes were
compared using the chi-square test for categorical vari-
ables and the Mann-Whitney-Wilcoxon rank sum test
for continuous variables. OS estimates were obtained
by the method of Kaplan and Meier, and comparisons
were made using the log rank test. The probability of
TRM was calculated using cumulative incidence esti-
mates. For the endpoint of TRM, disease progression
was regarded as a competing risk. Patients who died
without disease progression were categorized as
TRM, while patients alive without progression were
censored at last follow-up and those who suffered dis-
ease progression were censored at relapse. Patients
whohad relapsed andwhoafter donor lymphocyte infu-
sion (DLI) achieved further remission (CR2) were also
considered in CR, but this new status is explained in the
text.OSwas calculated from transplant until death from
any cause, and surviving patients were censored at last
follow-up. For patients achieving CR2, the time in re-
sponse was calculated only for the documented period
of each remission. The cumulative incidence and time
to onset of aGVHD and chronicGVHD (cGVHD) re-
quired that patients survived for at least 15 and 100 days
after transplant, respectively. Multifactorial non-linear
regression was used to analyze the possible relationship
between survival and the following co-variates: type of
malignancy, patient gender, patient age, donor sex, an-
tibody dose, and stem cell dose. All data analyses were
performed using the Statistica (StatSoft Inc. Tulsa
OK) computer software package.
RESULTS
Eighty-one consecutive and unselected patients
with hematological malignancies were referred to the
transplant program and agreed to participate in this
study, fulfilling the guidelines of the University of
Cape Town and Groote Schuur Hospital. All received
cytokine mobilized PBPC transplants from their HLA
identical sibling donors. Their clinical and demo-
graphic data are shown in Table 1. The median age
of the study population was 45 yrs (range 15-60) and
21 individuals were aged 50 years or older. Following
cytokine-mediated mobilization of progenitor cells,
a median of 9.85  108/kg MNC containing a median
of 2.66 CD341  106/kg and 14.2 (range 1.2-88)
CFUGM  104/kg were harvested. For ex vivo treat-
ment of the grafts, the first 27 patients received median
20mg (range 7.5-50) ofCAMPATH-1H (2mg1010 /
MNC). The following 54 patients’ grafts were treated
a reduced dose of (1 mg  1010 / MNC) and here the
median dose received was 10 mg (range 5-25). For
the whole group, median follow up is 777 (range 7-
2702) days, when 78% survive and 73% are disease-
free (Figure 1). In the current study, the patients’ age
712 N. Novitzky et al.Table 1. Clinical and laboratory parameters, conditioning methods and characteristics of the stem cell grafts in the study population
All patients (n 5 81) Alive (n 5 61) Dead (n 5 20)
Age in yrs, median (range) 45 (15-60) 43 (15-58) 47 (18-60); p5 0.1
Sex M/F 49/32 37/24 12/8
Diagnosis:
Acute leukemia & MDS 35 24 11
AML 25 17 8
MDS 5 4 1
ALL 5 3 2
MPD 16 12 4
CML 12 10 2
Myelofibrosis 2 1 1
CMML 1 0 1
P. Vera 1 1 0
NHL 22 18 4
Follicular/ CLL 8/1 7/0 1/1
Transformed LC/DLCB 6/1 6/1 0
Mantle 2 1 1
T cell 2 2 0
Hodgkin 2 1 1
MM 8 7 1
Dose of CAMPATH-1H mg, median (range) 10 (7.5-50) 10 (7.5-50) 13.5 (7.5-35) P 5 .04
Conditioning: Radiotherapy/Chemotherapy 45/36 35/26 10/10 P 5 .40
CD341  106/kg infused, median (range) 2.66 (1.14-12.3) 2.85 (1.14- 12.3) 2.34 (1.31-4.56) P 5 .02
Recovery leukocytes to . 0.5 109/L 12 (9-35) 11 (9-17) 12 (9-35) P 5 .10
GvHD, any (%) 8 (10%) 3 (5%) 5 (26%) P 5 .01(above or below median age) was not adversely associ-
ated with outcome (data not shown). Conditioning was
chemotherapy-based in 36 individuals, while the re-
mainder received radiotherapy. At transplantation,
their respective median ages were 47 and 42 yrs
(P5.55); there was no difference in the survival in the
2 treatment groups (75% and 78%, at median follow
up of 608 and 950 days, respectively).
Engraftment
One patient died on day 7 fromC. Albicans species
infection in septic shock. All other patients engrafted.
The median time to reach 0.5  109/L granulocytes
and unsupported 50  109/L platelets was 13 (range
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Figure 1. Overall survival of the patient population.10-35) days. Forty-seven patients received a stem cell
graft from an opposite gender donor. A karyotype
analysis of their marrow cells performed at 3 mos
post-transplantation showed full donor chimerism in
each case.
Graft-versus-Host Disease
Following transplantation, clinically relevant
aGVHD (greater than stage I) was present in 6 patients
(of 80 at risk; 7.5%), which progressed to stage III in 2
individuals and to stage IV in 1 individual (Tables 2 and
3). Except for the last case, all improved on systemic
corticosteroids and cyclosporin. Any form of GVHD
was observed in 8 patients (10%). Five developed
Table 2.The incidence of Graft-versus-Host Disease and relapses according
to diagnosis are shown
Treatment outcome (n)
GVHD
Any 8
Acute 6
Chronic 5
GVHD post DLI 3/17
Overall relapses
CML / MPS 7/3
AL 4
NHL 1
MM 3
% surviving 75
Relapse free survival, median days (range) 879 (2091-132)
Overall survival, median days (range) 777 (7-1246)
Improving Tolerance to Myeloablative Conditioning by T Cell Depletion 713cGVHD (2, extensive disease); 3 progressed following
an initial acute phase. In total, 6 of 8 individuals with
GVHD died of infections. One subject died of uncon-
trolled GVHD in liver failure. All these patients had at
least one admission to hospital for the treatment of as-
sociated severe opportunistic infection. One patient
had 4 admissions with various bacterial or viral infec-
tions and died of sepsis. In addition, following recur-
rence of the malignancy (n 5 13) or for prophylaxis
of relapse, 17 individuals receivedDLI and 3 developed
GVHD (grades II, II and III respectively) and 2 died of
sepsis. Figure 2 shows that GVHD occurrence was
associated with adverse outcome (P 5 .002 log Rank).
Outcome according to diagnosis (Figure 3)
The patient details grouped according to diagnosis
and their clinical characteristics are shown in Table 1
and 3.
Acute leukemia and myelodysplastic syn-
dromes (MDS): Thirty-five patients received trans-
plants for high risk MDS (n 5 5) or acute leukemia
(AML) (n 5 25) and currently their median follow
up is 555 days (range 7-2104). In subjects with AML,
Table 3. The treatment related mortality and disease recurrence rates are
shown
Cause of Death n 5 (%)
Treatment related Mortality 15
Infections 8 (10%)
GVHD 2 (2.5%)
VOD 3 (4%)
Various
Interstitial pneumonia 1
Lymphoma post transplant 1
Disease relapse 5 (6%)
GVHD indicater graft-versus-host disease; VOD, veno occlusive
disease.
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Figure 2. Survival according to occurrence of GVHD.karyotype risk was defined according to Keating et al
[20]. In this group, 5 had low risk cytogenetics
(t(8;21)), 13 individuals had intermediate risk and 7
had high risk karyotype abnormalities. Their median
age was 39.5 yrs. Transplantation was performed in 6
individuals in .CR1. Another 5 patients had high-
risk MDS (refractory cytopenia with multilineage dys-
plasia n5 3; RAEB-2 n5 2) and except for 1 who died
of veno occlusive disease (VOD), all survive in CR. In
the lymphoblastic leukaemia group (n5 5), themedian
age at transplantation was 27 yrs. Two had initially
presented with hyperleukcocytosis, 1 required 6
weekly courses to enter CR and 2 on initial cytogenet-
ics, had t(4;11). One individual developed meningeal
disease. Transplantation was performed in first remis-
sion in 4 patients and in CR2 in the rest.
Amongpatientswith leukemia andMDS, treatment
failure was mainly due to infections (n 5 4), VOD
(n5 3), and only 3 patients (acute lymphoblastic leuke-
mia (ALL) in CR2 in each case; AML in CR; 2 in 1 in-
stance) died directly of disease recurrence. The day 100
mortalitywas 8%,while overallTRMwas 20.5%. In to-
tal, 67% of these patients survive disease free at median
of 641 days and 55% are projected to survive leukemia
free beyond 1200 days.
Sixteen patients had myeloproliferative syn-
dromes (MPS) (including 12 with CML) and their
median age was 41 yrs (range 16 – 58). Seven patients
with CML had evidence of molecular (n 5 3) or cyto-
genetic (n5 4) recurrence after transplantation. From
graft infusion to relapse, the median interval was 6
months. All have achievedmolecular remission follow-
ing escalating doses of donor CD31 cells (median 1
107/kg; range 1 106/kg – 1.5 108/kg) and except for
1 who developed mainly cutaneous GVHD, without
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Figure 3. Survival according to diagnosis. The difference in the out-
comes is not significant. CML indicates chronic myelogenous leuke-
mia; NHL, non-hodgkin’s lymphoma; MM, multiple myeloma; AL,
acute leukemia.
714 N. Novitzky et al.complications [17]. Four patients with CML were
BCR/ABL negative and received at 6 months median
of 10  106 (range 5-10  106)/kg prophylactic donor
CD3 cells. One died of pneumonia. The rest remain in
molecular CR1, with a median of 4 yrs. Therefore, 10
(including 7 relapsed patients) of 12 (83%) patients
with CML currently are in molecular remission
(CR1 or CR2). Four individuals had other MPS (poly-
cythemia vera 1; myelofibrosis 2; chronic myelomono-
cytic leukemia [CMML] 1). Both patients with
myelofibrosis relapsed and responded to DLI, but 1
developed extensive cGVHD and died of recurrent in-
fections. Within the whole group (n 5 16), 4 patients
died. Two patients died of recurrence of the malig-
nancy (1 with myelofibrosis, from GVHD following
DLI; and a patient with CMML, from disease
progression at 448 days) and another 2 with CML of
multilobar pneumonia and post-transplant hepatic
lymphoma (EBV1), respectively. At a median of 922
days, 75% individuals survive and no further events
occurred after 1200 days.
Recurrent chemo-sensitive lymphoma was the
indication for transplantation in 22 individuals. The
histology was low grade of B-cell origin in 9 (8 follicu-
lar NHL; all with initial short response to therapy),
transformed histology to diffuse large cell lymphoma
(DLCL) in 6, and another had DLCL in CR2 who
had failed to mobilize stem cell for autologous trans-
plantation. In addition, 2 patients each with mantle
cell or of peripheral T cell phenotype were trans-
planted in CR1. Two patients had Hodgkin disease
in 3rd remission and failed to mobilize stem cells. For
the whole group (n5 22) the median number of treat-
ments before transplantation was 3 (range 1-7). Four
patients died of transplant related causes (GVHD: 1;
infection: 2; interstitial pneumonitis: 1). One with
T cell lymphoma had recurrence of the malignancy
and has responded to salvage therapy with DLI.
GVHD occurred in 2 of 4 patients who died, but only
in 1 of 18 of those surviving (P5.02, Fisher’s exact test).
Eight patients withmultiple myeloma (MM) had
treatment responsive disease and, at the time of trans-
plantation, 5 were in CR following steroid based com-
binations or previous autologous stem cell transplants.
Median age at transplantation was 46 yrs (range 30-
55). One individual died of multilobar pneumonia at
115 days after graft infusion. Three patients relapsed;
they received salvage therapy with thalidomide in
combination with donor lymphocyte infusions and 2
achieved further remission. At median of 820 days,
6 are off all therapy in response on bone marrow
morphological examination, as well as serum immuno-
fixation studies [13]. One individual has received DLI,
but has not been evaluated for response. Currently 7/8
patients are alive at a median of 820 days (115-1591).
Actuarial 2-yr survival in remission (CR1 or CR2) is
75%.TRM and OS
Twenty patients died. Table 3 details the causes of
TRM. By day 100 and 1 yr post transplant, respec-
tively, 7 and 11 patients had died (accumulated TRM
at day 100 and 1 year was 7% and 15.6% respectively)
of treatment related causes, while Figure 4 shows that
at 3 yrs, accumulative NRMwas 20.5%. The same fig-
ure also depicts that, during the observation period,
cumulative recurrence of malignancy was 25.7%, but
11 patients survive in successive remission following
DLI. Survival following hematopoietic stem cell trans-
plantation (HSCT) is shown in Figure 1, and described
inTables 2 and 3. At amedian follow up of 777 days (7-
2100 days), 78% are alive, 73% remain disease free (11
in CR2 after DLI). At 3 yrs, 71% of the patients are
projected to continue alive, without malignancy.
There was no significant difference in the outcome
of patients transplanted in the years 2000-2002 and
2003-2005 (P5 .60; log Rank).
Outcome
Patients who survived after SCT received signifi-
cantly higher CD341 cells x106/kg dose (median
2.85; range 1.14-12.3) than those who failed therapy
(median 2.34; range 1.31-4.56; P5 .02) and had
received a lower dose of CAMPATH1-H in the bag
(median 10 mg; range 7.5-50; vs 13 mg; range 7.5-35;
P5.04) (Table 1). Analysis was focused on 3-yr out-
comes. Univariate analysis showed that dose of CD341
cells infused in the graft and dose of alemtuzumab
added ‘‘in the bag’’ and the occurrence of GVHD
were significant factors for survival (Figure 3). Multi-
variate analysis failed to show that age at transplanta-
tion or types of malignancy were significant factors.
Proportional hazards (Cox) regression analysis
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Figure 4. Treatment related mortality (TRM) and treatment failure
due to disease recurrance is shown. It must be noted that 11 of these
patients who relapsed (Rel) are alive in further remission following
DLI.
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long-term survival.
Toxicity (Table 4)
Following myeloablative conditioning, pyrexia re-
quiring i.v. antibiotics was seen in 91% of patients and
2 died of unresponsive C. albicans sepsis. Radiother-
apy based preparation was well-tolerated and only 17
patients developed gastrointestinal toxicity greater
thanWHO 2. Three patients developed idiopathic in-
terstitial pneumonia that resolved following steroid
therapy in 1 patient. One patient who also had idio-
pathic pneumonitis developed fatal VOD. In the
chemotherapy conditioning cohort, 18 patients devel-
oped greater than grade 2 mucositis and another 2 in-
dividuals had portal vein thrombosis, but all reversed
following conventional supportive therapy. Three pa-
tient developed fatal VOD of the liver, despite heparin
prophylaxis. Three patient / donor pairs were CMV-
nonreactive. Reactivation of CMV infection was seen
in 16/77 at risk (21%) individuals. Median time to di-
agnosis of infection was 49 days (35-119 days). Infec-
tion was detected by a reactive pp65 test (n513) or
histological confirmation of the virus on colonoscopy
(n53); all responded to gancyclovir therapy without
developing disseminated disease. One patient died of
adenovirus viremia and hemorrhagic cystitis compli-
cated by Gram negative bacterial sepsis.
DISCUSSION
Themain limitations in the success of SCT remain
TRM, particularly with standard conditioning and, in
malignant disorders, disease recurrence. Indeed, with
myeloablative doses, first year mortality rates as high
as 40% have been described by some investigators,
even in individuals with good performance status, con-
sequently excluding older [23,24] patients and those
with a more compromised general condition [4,5,23].
For this reason, schedules that had significant reduc-
tions in the conditioning doses, but that remained
mainly immunosuppressive, have been developed and
are collectively referred to as reduced intensity condi-
tioning (RIC) regimens. Without the initial myeloa-
blative doses, these patients are only protected by the
so called ‘‘graft-versus-tumor effect’’ (GVL) that
appears associated to GVHD, which then becomes
the main if not the ultimate mechanism for disease
Table 4. Toxicity of the myeloablative conditioning
Organ toxicity (WHO) %
Mucositis 21
Pneumonitis 4
Veno-occlusive disease 4
Portal vein thrombosis 4
Pyrexia . 38C 91clearance. There are substantial limitations in this ap-
proach, however, as these strategies are frequently as-
sociated with aGVHD and cGVHD [8,23-26] which
in the advanced grades has been recognized as unfavor-
able factor for survival. It is therefore not surprising
that relapse rates are high, particularly in patients
who have the more rapidly proliferating malignancies
that seem to overcome the slow recovery of immune
surveillance [25,26].
Numerous RIC regimens have been described, but
many reports relate mainly to small and heterogeneous
groups of patients with limited follow up, thus
currently the ‘‘optimal’’ RIC regimen is unknown.
Martino et al [27] compared the outcome of 621 pa-
tients undergoing myeloablative conditioning with
215 who were significantly older and had received
RIC and unfractionated stem cell grafts. The latter
group had higher risk disease and significantly more
subjects had received a previous autologous SCT.
Following transplantation, NRM at 100 days and 3
yrs were significantly lower in RIC group, but the cu-
mulative risk of relapse higher. Consequently, OS was
no different between the 2 cohorts. Alyea et al [28] also
compared these 2 modalities in patients with leukemia.
The RIC group had also more patients with refractory
disease and of older age. The incidence and severity of
aGVHD was similar (27% & 29%) and the 100 day
mortality was lower in the RIC group (6% vs 30%),
which was at the expense of higher cumulative relapses.
The cumulative NRMwas 32% in the RIC and 50% in
myeloablative group (P5.01). OS at 2 years was not
significantly different.
Leukemia in older patients is often refractory to
chemotherapy and these patients may rely only on
the effects of GVL. Thus with RIC, cure may occur
in approximately 30% of older patients, whereas dose
intensity seems to lead to toxicity with little further
benefit. De Lima et al [29] however, found signifi-
cantly better levels of chimerism, lower relapses, and
improved outcome in younger individuals receiving
a more intensive conditioning strategy, suggesting
that dose intensity may be of relevance. It remains
unclear if, for younger individuals, RIC also leads to
better survival as in their disease type, the cost benefit
ratio may favor dose intensity rather than GVHD/
GVL. Moreover, there are yet no long-term results
to confirm that protection from disease recurrence is
universal and long-standing. On the other hand, even
in the younger patients, GVHD causes substantial
morbidity and mortality, particularly through a higher
infection risk. A further complicating factor of exten-
sive GVHD is the need for prolonged and powerful
immunosuppressive therapy, leading to early and late
opportunistic infections that also adversely affect
survival [26,27].
T cell depletion reduces significantly the incidence
and severity of this complication and thus, of extended
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ated with acceptable outcome, as in this cohort median
survival has not been reached [14-16,30]. For instance,
Canals et al [31] compared the outcome of patients
transplanted following myeloablative conditioning
and T cell depletion by CD341 selection with
a matched group who received RIC and un-fraction-
ated grafts. In the latter group, NRM at 1 yr was sub-
stantial (39%) and mainly due to infections, while in
the first group, the rate of death was similar to the cur-
rent report, and was largely caused by GVHD and re-
lated infections [15]. TRM with this method would
seem to be similar to the experience described with
CAMPATH-1H antibodies in earlier publications
[13,14]. However, as a difference to some of these T
cell depletion techniques, ex vivo incubation of the
graft with alemtuzumab is simple and does not require
expensive technology. Cells expressing the CD52 anti-
gen are coated by the antibody and later removed by
the phagocytic system in vivo.
In the present report, ex vivo T cell depletion with
CAMPATH-1H antibody led to excellent engraft-
ment rates, with low incidence of GVHD. In this
cohort, due to logistical reasons, 2 myeloablative
conditioning regimens were used, but no significant
difference with regards to the toxicity profile, engraft-
ment rates, and long-term survival was encountered.
Only 4 patients had features of VOD of the liver, while
the rate of reactivation of CMV (21%) or other viral
infections was not substantial. Recurrence of malig-
nancy was seen in 21% (15 of 70 at risk) (Table 3).
Except for those with CML, this conditioning sched-
ule was highly protective of disease relapse. Neverthe-
less, escalating doses of DLI given during recurrence
led to rapid clearance of the BCR/ABL genetic marker
in CML and of the paraprotein (on immunofixation) in
myeloma, with low rates of GVHD. For this reason,
we offer DLI as prophylaxis of relapse in CML even
if molecular studies have remained normal, as in our
experience most of these individuals will eventually
progress [17, 14], while after graded doses of DLI,
GVHD seems to been a less serious clinical problem.
Despite advanced malignancy and in 2 cases, moderate
renal failure, individuals withMMdid particularly well
and 6 survive disease free at a median of 752 days, on
no therapy. One is currently receiving DLI for re-
lapsed myeloma. At a median follow up of 777 days
from transplantation 78% of patients survive. The cu-
mulative 1 yr and overall NRM were 15.6% and
24.3%, which is similar to that reported with RIC pre-
paratory schedules (Figures 1 and 4). Overall GVHD
(grade II-IV) was a rare complication, seen only in
10%, and 16% if the 17 patients who received DLI
are included. However, Figure 2 shows that among pa-
tients who had not developed GVHD, with median
follow up of 790 days, OS was of 85% and regression
analysis confirmed that GVHD was associated witha worse outcome (P5.002). Moreover, it could be ar-
gued that fewer of these patients had refractory malig-
nancy or a previous SCT, but 71% 3-yr survival of this
cohort confirms that if TRM is low, then proceeding
earlier to allogeneic SCT is justified. A weakness of
this study however, is the heterogeneity of the diag-
nostic patient groups, which makes comparison of
disease recurrence rates with other series more
complex.
Depletion of immune effector cells for the preven-
tion of GVHD has been used in a number of studies
and ranged from in vivo treatment of the patients
with polyclonal immunoglobulins such as anti-
lymphocyte globulin [32], the use of broad ranging
lympholytic activity mAbs such as CAMPATH-1
[14,33], selection of CD341 cells [31,34], or alterna-
tively use of narrow specificity anti-T cell antibodies
[35,36]. We believe that the current combined sched-
ule of low dose CAMPATH-1H ‘‘in the bag’’ (median
10mg) and post-transplant cyclosporin, has resulted in
the current low rates of GVHD and good survival
rates. A similar strategy of T cell depletion has been
found to be effective in another smaller study when
CAMPATH-1 was also used in lower doses, as patients
seemed to have superior immune recovery [37]. On the
other hand, when CAMPATH-1H was injected into
patients at doses ranging from 60-100 mg, it has
been linked with reactivation of endogenous viruses
and increased TRM [38,39]. The higher doses of alem-
tuzumab employed together with a slow antibody
clearance [40] characteristic of this humanized protein,
appear to limit ongoing immune reconstitution and
predispose to opportunistic infections and thus re-
sulted in no advantage in survival [38]. Lastly, to be
able to compare strategies, it must also be kept in
mind that many series of standard dose conditioning
were published over 10 yrs ago, when supportive
methods were of lower complexity than at present.
For instance, and affirming this point, improvement
in survival in patients with myeloma have been re-
ported by Gahrton et al [41,42] in a review of the re-
cent data from the EBMT registry.
To be able to choose the best therapeutic modality
for an individual patient, all these alternatives require
adequate scrutiny based on prospective trials, but cur-
rently, such data is still not available. In the interim,
and based on the existing considerable experience, one
alternative would be to extendmyeloablative unfractio-
nated or T cell depleted transplantation until the age of
60 yrs in patients who have adequate performance sta-
tus, because with such modality, we can expect long-
term survival rates in excess of 70%. Patients with
known contraindications to high dose conditioning
schedules, butwhohave indolentmalignancies (chemo-
therapy responsive follicular lymphomas, etc) would be
ideal candidates to receiveRIC.Reductionof transplant
toxicity and of early mortality as is currently observed,
Improving Tolerance to Myeloablative Conditioning by T Cell Depletion 717may justify an earlier choice of allogeneic SCT before
malignancies have become refractory.
In conclusion, this study confirms our earlier ob-
servation that in patients with adequate performance
status and with responsive hematological malignancy,
by reducing the risk and severity of GVHD, myeloa-
blative doses of conditioning followed by ex vivoT cell
depletion with anti-CD52 was well tolerated, with low
rates of morbidity or mortality. However, the specific
place of each modality will require the guidance of
prospectively conducted controlled trials.
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